Get email updates from SABCSMeetingNews.org
Subscribe to get regular news updates from SABCS.org and SABCS Meeting News.
The 2023 SABCS® was a huge success, with record attendance and number of submitted abstracts. The premier symposium for breast cancer research, care, and advocacy had plenty of new features, as well as the robust science that is the meeting’s hallmark.
Heide L. Ford, PhD; Jennifer K. Richer, PhD; Ann Partridge, MD, MPH; and Mariana Chavez Mac Gregor, MD, MSC, FASCO, outlined updates across the spectrum of breast cancer research and clinical practice.
Experts reviewed the updates from the 2023 SABCS® that may have an immediate impact for patients and physicians.
Vivek Subbiah, MD, and fellow panelists explored how genomics are driving a new era of tumor-agnostic therapies for cancer in which drugs are approved for biomarkers rather than cancer types.
Findings from 11 studies were presented Friday during the third and final General Session of the 2023 SABCS®.
Alana L. Welm, PhD, on Friday discussed what she was doing to model metastatic breast tumors using patient-derived xenografts and organoids, and she implored her fellow researchers to work together to advance the field.
Audience members brought real-world clinical cases and concerns before a multidisciplinary panel on Thursday, prompting discussions about choosing optimal care and treatment for patients with breast cancer in routine practice.
Aditya Bardia, MD, breast medical oncologist at Massachusetts General Hospital, and Saba Shaikh, MD, breast medical oncologist at Mays Cancer Center at UT Health San Antonio, discuss antibody-drug conjugates.
Komal Jhaveri, MD, clinical director for early drug development service at Memorial Sloan Kettering Cancer Center, and Saba Shaikh, MD, breast medical oncologist at Mays Cancer Center at UT Health San Antonio, discuss the DESTINY-Breast08 trial.
Nolan Priedigkeit, MD, PhD, medical oncology fellow at Dana-Farber Cancer Institute, and Andrew Brenner, MD, professor of medicine and breast medical oncologist at Mays Cancer Center at UT Health San Antonio, discuss fusion RNAs and metastatic breast cancer.